MESSAGE FROM THE DIRECTOR

The Experimental Therapeutics Institute serves as the interdisciplinary institutional platform for the development of new drugs, devices, and intellectual property that grow out of Mount Sinai’s basic and clinical research projects.

The Institute provides a range of emerging and established technologies for Mount Sinai researchers that enable the translation of basic biological mechanisms into therapeutics. The core services provided by the Institute include high-throughput screening of chemical libraries, medicinal chemistry, pharmacokinetics and pharmacodynamics, and computation and systems pharmacology. Institute members come from 19 basic and clinical departments across Mount Sinai.

The Experimental Therapeutics Institute is an important component of The Mount Sinai Medical Center’s clinical and translational research activities. Applying Clinical and Translational Science Award funds from the National Institutes of Health, the Experimental Therapeutics Institute competitively supports a number of pilot project grants to foster cutting-edge translational research. The Institute also funds research fellowships to develop the new generation of clinical and translational researchers.

The Experimental Therapeutics Institute works closely with the Mount Sinai Office of Technology and Business Development to provide a seamless pipeline for the advancement of new drugs and therapies, including the organization of joint activities such as seminars and workshops. The Office of Technology and Business Development has an Innovation Fund that competitively funds projects to enhance their near-term potential for commercialization. The Institute receives its support from philanthropic funds as well as Clinical and Translational Science Awards from the National Center for Research Resources.

Ravi Iyengar, PhD
Director, Experimental Therapeutics Institute